EMA and FDA prune the checkpoint inhibitor treatment landscape

Nat Rev Urol. 2018 Oct;15(10):596-597. doi: 10.1038/s41585-018-0074-1.

¹ Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
² Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. rosenbj1@mskcc.org.

No abstract available